Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

LUNG CANCER

Dual PD-L1 and CTLA4 inhibition in ES-SCLC

Nature Reviews Clinical Oncology volume 18, page 64 (2021)Cite this article

Subjects

In March 2020, the FDA approved the anti-PD-L1 antibody durvalumab in combination with first-line platinum–etoposide chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC), based on interim overall survival (OS) data from the phase III CASPIAN trial. Updated results of this trial confirm the benefit of this combination (median OS 12.9 months versus 10.5 months with chemotherapy alone; HR 0.75; nominal P = 0.003). However, a primary analysis of OS in a third arm of this trial showed no benefit from adding both durvalumab and the anti-CTLA4 antibody tremelimumab to chemotherapy: median 10.4 months versus 10.5 months with chemotherapy alone (HR 0.82; P = 0.05). This finding might reflect the increased incidence of toxicities with the tremelimumab-containing regimen and related reductions in overall levels of exposure to both durvalumab and chemotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • Goldman, J. W. et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(20)30539-8 (2020)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    David Killock

Authors
  1. David Killock
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Killock.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Killock, D. Dual PD-L1 and CTLA4 inhibition in ES-SCLC. Nat Rev Clin Oncol 18, 64 (2021). https://doi.org/10.1038/s41571-020-00466-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-020-00466-w

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing